Drug Detail

Information about Votrient + Hycamtin

Generic Name	Pazopanib + Topetecan
IND
Brand Name (US)	Votrient + Hycamtin
Manufacturer	GlaxoSmithKline
Drug Type	Tyrosine Kinase Inhibitor + Chemotherapy
Delivery	Oral
Approval Status	Both are approved for non-GIST applications
Indications	Kidney cancer, ovarian cancer, cervical cancer, SCLS
Overall Strategy	KIT Protein + GIST cell based
Strategy	Block KIT + Unblock cell death genes
Drug Category	KIT/PDGFRA inhibitor + topoisomerase inhibitor

Pazopanib is a potent VEGFR inhibitor but it also inhibits KIT and PDGFRs. It is entering a phase II trial for GIST (~spring 2011).
Topetecan is a topoisomerase I inhibitor.